All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld Perspectives » Four Days Later: The De-Evolution of a #2011BIO Attendee

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Four Days Later: The De-Evolution of a #2011BIO Attendee

June 30, 2011
By Jennifer Boggs
No Comments

Assistant Managing Editor

This year marked my fifth BIO International Convention since joining the BioWorld team. I love the BIO meeting. It’s a great way to learn about new trends in the industry, discover potential sources for future BioWorld stories and finally put a lot of faces to names of people I’ve only talked to over the phone. Plus, the parties are fun. But it is a completely crazy schedule. And every year, I’ve found myself moving from different levels of alertness and exhaustion over the four-day period, though I admit a lot of is my own fault for trying to do too much. Here’s my typical BIO progression: Day One: I’m awake before the alarm goes off. I get to the convention center early, so I can orient myself, figure out where all my meetings and sessions are. I’ve got an ambitious schedule, but that’s OK. I feel good. Sharp. The ideas are flowing, and I go all day through the welcome reception without much of a break. Day Two: It takes me a little longer to get going this morning. But I’m still feeling good. I hit all the sessions and interviews on my schedule, write my stories for BioWorld Today and still have a couple of hours to traipse through the massive exhibit hall. Day Three: I hit the snooze button four times. My feet hurt – perhaps that exhibit hall expedition the day before was not such a great idea. But I persevere. Despite my tiredness, I keep up with the schedule, mostly. I make it to the sessions and continue taking notes, though some of my notes don’t make any sense when I read over them later. “Campy potential hobbits biotech,” my notes from one session say. I have no clue what that means. By late afternoon, I start suffering a few temporary fugue states, and my brain starts flashing images of the down comforter and pillow from my hotel room, and I think wistfully how nice it would be to curl up for a few hours of sleep. Instead, I go out for another late night. Day Four: It’s a blur. Somehow I get lost on my way to the press room. I start alternating between punchy and stuporous. At one point, I nearly start cackling like a loon because I realize I’ve forgotten how to spell “protein.” Shouldn’t it be “i” before “e”? Isn’t that the rule? Huh? Spellcheck says “protein.” That just looks weird, though. What a strange word. Protein. You’ve got your pro, you’ve got your tein. Protein, protein, protein. By the time the conference winds down, I’m approaching zombie territory. And I’m not the only one. There are a lot of zombies walking around on the last day. We bob our heads at each other and say our goodbyes in our new zombie language – it’s kind of a monosyllabic sort of speech – and mechanically hand over the last of our business cards. Then we head home to recover. Yep. Good times. I can’t wait do to it again in Boston next year!

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing